TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02058745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartCare
Description: SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
Study: NCT00550537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue collection.
Study: NCT00306462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nifedipine or placebo
Description: Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
Study: NCT01523730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Repetitive Transcranial Stimulation (rTMS)
Description: Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection
Study: NCT01916291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propess insertion group
Study: NCT02412813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LEGION OXINIUM
Description: Investigational Group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LEGION Cobalt Chrome
Description: Control Group
Study: NCT02031328

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for injection, Subcutaneous injection
Study: NCT00317291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture/Moxibustion
Description: Acupuncture/Moxibustion: 16 scheduled sessions
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for injection, Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution for injection, Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Study: NCT00317291

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture/Placebo moxibustion
Description: Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
Study: NCT02006095

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used

Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Study: NCT04441190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Action Observation Therapy (Digital AOT)
Description: The participants will be asked to observe videos and then practice what the participants observed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mirror Therapy (Digital MT)
Description: The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
Study: NCT03472547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
Study: NCT01949467

Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.

Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.

Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.

Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
Study: NCT01957956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01949467

Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
Study: NCT00535288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
Study: NCT01822314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
Study: NCT05181280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Exposure session will consist of 15 social media ideal body message posts.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Exposure will consist of 15 social media posts on infant feeding tips.
Study: NCT00639652

Intervention type: PROCEDURE
Intervention: 3D-histology
Description: The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.

Intervention type: PROCEDURE
Intervention: Shave excision
Description: Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
Study: NCT00319267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
Study: NCT04698577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
Study: NCT02702297

Intervention type: OTHER
Intervention: single arm
Description: Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
Study: NCT05616689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled hyperpolypharmacy
Description: Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
Study: NCT02929043

Intervention type: OTHER
Intervention: air puffs
Study: NCT01957956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02867631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
Description: 6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
Study: NCT00962715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Trivalent Inactivated (TIV)
Description: 15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Trivalent Inactivated (TIV)
Description: 15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Trivalent Inactivated (TIV)
Description: 15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEGrIFN-α, Pegasys)
Description: 180 μg (0.5 ml) before receiving TIV, through a needle under the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon (IFNα, Roferon-A)
Description: 3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
Study: NCT04680650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia was maintained with sevoflurane
Description: After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia was maintained with propofol
Description: After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
Study: NCT03931018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
Study: NCT02769598

Intervention type: DEVICE
Intervention: ANI Index for Hospitalized children
Description: Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
Study: NCT01390545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
Study: NCT01026584

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: 6 week prospective study
Study: NCT02093611

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP
Description: 400 mg of ATP
Study: NCT00628186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drainage tube [polyethylene pancreatic drainage tube]
Description: External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal drainage tube [polyethylene pancreatic drainage tube]
Description: Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Study: NCT04340219

Intervention type: OTHER
Intervention: Survey administration
Description: Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
Study: NCT01263912

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCPUFA Supplement
Description: Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
Study: NCT02848729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Acetaminophen
Description: Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
Study: NCT01854047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed
Study: NCT02848729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Morphine
Description: Morphine for IV administration (0.125 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Morphine
Description: Morphine for IV administration (0.125 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Placebo tablets matching oral acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline placebo matching IV acetaminophen
Study: NCT01998984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed
Study: NCT01998984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01126047

Intervention type: OTHER
Group type: OTHER
Intervention: eCO testing
Description: exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
Study: NCT01165762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Tolerance
Description: Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting.
Study: NCT00361413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept (AMEVIVE®)
Description: Alefacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: these patients will receive the same treatment as group A, without alefacept